Understanding how estrogen affects breast cancer risk is one of the most confusing and highly searched topics in women’s health. In this episode of Off the Charts, Dr. Bobby Parmar, ND breaks down the science behind estrogen, breast density, hormone therapy (HRT), IUDs, birth control, IVF, pregnancy timing, breastfeeding, and other factors that shape breast cancer risk throughout a woman’s life.

We explain what “lifetime estrogen exposure” means, why early periods and late menopause matter, and how breast density, alcohol, height, metabolic health, and reproductive history all contribute to risk in different ways. We also clarify one of the biggest misconceptions circulating online: estrogen-only menopausal hormone therapy after hysterectomy is associated with lower breast cancer risk according to large randomized trials.

This episode gives women a clear, evidence-based understanding of breast cancer risk factors—without fear-based messaging or misinformation.

WHAT YOU’LL LEARN

How estrogen influences breast cancer risk across the lifespan

Estrogen’s benefits for bone, brain, metabolic and cardiovascular health

The truth about perimenopause, menopause and hormone therapy (HRT)

Breast density, BI-RADS categories and how density affects screening accuracy

Family history, atypia and combined breast cancer risk

Alcohol, height, growth hormones and metabolic contributors

Pregnancy timing, breastfeeding cycles and breast tissue biology

What studies actually show about IUDs, birth control and IVF

What women can and cannot control when it comes to breast cancer prevention

TOPICS COVERED (TIMELINE STYLE)

Why estrogen is misunderstood

What “lifetime estrogen exposure” really means

Menopause, HRT and clearing the confusion

Breast density, BI-RADS and cancer detection

Family history, atypia and stacked risks

How breast density changes with age

Alcohol as a Group 1 carcinogen and what studies show

Does alcohol type matter?

Height, growth hormones and cancer risk

Metabolic health, inflammation and early-life factors

Pregnancy timing and why age matters

Never having kids (nulliparity)

How breastfeeding changes breast tissue

What it means if you cannot breastfeed

IVF hormones and breast cancer risk

Birth control, hormonal IUDs and real-world numbers

Misinformation, fear-based messaging and how to understand your personal risk

EPISODE RESOURCES AND REFERENCES

Off the Charts provides a companion reference page for every episode to support transparency and evidence-based discussion. Key sources for Episode 2 include Frontiers in Oncology, The Lancet, Nature, the National Cancer Institute, the Canadian Cancer Society, FORCE XRAY, Susan G. Komen, Radiopaedia and the American College of Radiology (BI-RADS).

Primary studies and clinical resources:

Frontiers in Oncology – Estrogen Effects on the Mammary Gland
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00110/full 

PubMed – Estrogen-Alone Therapy and Breast Cancer Incidence (2024)
https://pubmed.ncbi.nlm.nih.gov/38653905/ 

FORCE XRAY – Estrogen-Only HRT and Breast Cancer
https://www.facingourrisk.org/XRAY/estrogen-without-progesterone-as-HRT-may-lower-breast-cancer 

Canadian Cancer Society – Breast Density
https://www.cancer.ca/en/treatments/tests-and-procedures/mammography/breast-density 

National Cancer Institute – Reproductive History and Cancer
https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/reproductive-history-fact-sheet 

Nature – Pregnancy Duration and Breast Cancer Risk
https://www.nature.com/articles/s41467-018-06748-3 

Susan G. Komen – Age at First Childbirth
https://www.komen.org/breast-cancer/risk-factor/age-at-first-childbirth 

Radiopaedia – Breast Density Classification
https://radiopaedia.org/articles/breast-density-classification 

American College of Radiology – BI-RADS
https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/BI-RADS 

CONNECT WITH GRAVITY HEALTH

Website: https://www.gravityhealthclinics.com/ 
Book a Consult: https://gravityhealth.janeapp.com/ 
Mint Reproductive Health: https://mintreproductivehealth.com/ 

FOLLOW US

Instagram (Clinic): https://www.instagram.com/gravityhealthclinics/ 
Dr. Bobby Parmar: https://www.instagram.com/docparmar_nd/ 
Dr. Paul Maximus: https://www.instagram.com/drmaximus/ 

DISCLAIMER

Off the Charts is a podcast by Gravity Health created for general informational and educational purposes only. It does not constitute medical advice, diagnosis or treatment. Listening to this podcast does not establish a doctor–patient relationship. Always seek the guidance of a qualified healthcare professional regarding your personal health concerns.

Terms of Use: https://www.gravityhealthclinics.com/terms-of-use 
Medical Disclaimer: https://www.gravityhealthclinics.com/medical-disclaimer

With Dr. Bobby Parmar and Dr. Paul Maximus
Brought to you by Gravity Health

“Behind the hype and hashtags, millions of people are quietly reshaping their health with GLP-1s, but the stigma hasn’t caught up to the science.”

Ozempic®, Mounjaro™, and other GLP-1 medications are changing how the world thinks about metabolism, weight, and longevity — but not without controversy.

In this conversation, Dr. Bobby Parmar and Dr. Paul Maximus explore how these drugs went from diabetes treatments to cultural lightning rods. They dig into what science really says about GLP-1s, why moral bias still shapes how we talk about obesity, and what this shift means for the future of health and medicine.

You’ll walk away with a deeper understanding of the biology behind appetite, the psychology of shame, and how longevity isn’t just about living longer — it’s about living better.

The physiological role of GLP-1 hormones in regulating hunger, satiety, and blood sugar

Why these treatments are helping patients with metabolic and cardiovascular disease — not just weight

The history of fat-shaming and why stigma still affects treatment access

How obesity is now understood as a chronic, relapsing condition — not a personal failure

What the research shows about long-term safety, muscle preservation, and sustained metabolic improvement

0:00 Welcome to Off the Charts: The truth about GLP-1s and Ozempic
0:52 Why people hide their use of Ozempic and Mounjaro
2:52 Shame, willpower, and moral judgment in weight loss
4:55 Obesity as a disease — from circus cages to modern medicine
8:16 Fatphobia in healthcare and everyday life
9:13 Food noise, dopamine, and how our brains drive eating behavior
10:33 It’s not willpower — how biology shapes weight
13:55 The “cheating” narrative and natural vs pharmaceutical myths
15:31 The Gila monster story — how nature led to GLP-1 discovery
21:47 The rise of GLP-1 drugs and the billion-dollar shift
27:28 Why some doctors won’t prescribe Ozempic
32:30 Debunking “dangerous side effect” myths
37:27 Chronic disease, longevity, and why GLP-1s are for life
44:15 Muscle loss myths — what actually happens on Ozempic
48:38 Closing thoughts — send us your questions and hot takes

To maintain transparency and support evidence-based discussion, every Off the Charts episode includes a companion page listing all primary research, clinical trials, and cultural references mentioned in the conversation.

These references include publications from the New England Journal of Medicine, Physiological Reviews, the FDA, Obesity Canada, and more.

1️⃣ Holst JJ (2007). The physiology of glucagon-like peptide-1 (GLP-1). Physiological Reviews.
🔗 https://journals.physiology.org/doi/full/10.1152/physrev.00034.2006 

2️⃣ Drucker DJ (2018). Mechanisms of action and therapeutic application of GLP-1 and GIP. Cell Metabolism.
🔗 https://pubmed.ncbi.nlm.nih.gov/29617641/ 

3️⃣ Liraglutide and cardiovascular outcomes in type 2 diabetes. (2016). New England Journal of Medicine.
🔗 https://www.nejm.org/doi/full/10.1056/NEJMoa1603827 

4️⃣ U.S. Food and Drug Administration (2024). FDA approves first treatment to reduce risk of serious heart problems in adults with obesity or overweight.
🔗 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or 

5️⃣ Obesity Canada (2025). Recognizing and reducing weight bias in obesity management.
🔗 https://obesitycanada.ca/wp-content/uploads/2025/03/1-Canadian-Adult-Obesity-CPG-Reducing-Weight-Bias-Stigma.pdf 

This resource page is for educational purposes only and does not constitute medical advice.

Website → https://www.gravityhealthclinics.com/ 
YouTube  → Watch on YouTube
Book a Consult → https://gravityhealth.janeapp.com/ 

Instagram → https://www.instagram.com/gravityhealthclinics/ 
Dr. Bobby Parmar → https://www.instagram.com/docparmar_nd/ 
Dr. Paul Maximus → https://www.instagram.com/drmaximus/ 

Off the Charts is a podcast by Gravity Health, created for general informational and educational purposes only. It does not constitute the practice of medicine, nursing, or any other healthcare service and should not be taken as medical advice. Listening to this podcast does not create a doctor–patient relationship.

Listeners should always seek the guidance of qualified healthcare professionals regarding any medical condition or treatment.

For more information about content use and disclaimers, please visit:
https://www.gravityhealthclinics.com/terms-of-use 
https://www.gravityhealthclinics.com/medical-disclaimer